Tyvaso DPI: Drug-device characteristics and patient clinical considerations

By sjmartinez • November 16, 2023

McEvoy C, Argula R, Sahay S, Shapiro S, Eagan C, Hickey AJ, Smutney C, Dillon C, Winkler T, Davis B, Broderick M, Burger C. Tyvaso DPI: Drug-device characteristics and patient clinical considerations. Pulm Pharmacol Ther. 2023 Nov 13:102266. doi: 10.1016/j.pupt.2023.102266. Epub ahead of print. PMID: 37967762.

Tags: Cardiology/Epi, Inhaled, prostacyclin, Publications, pulmonary arterial hypertension, pulmonary drug delivery, Pulmonary hypertension with interstitial lung disease, Treprostinil, Veterans Administration

Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension

Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, Hackley S, Vogt S, Abreu P, Haughie S, Hassan T, Oudiz RJ. Randomized,[...]

In-hospital and readmission outcomes of patients with cancer admitted for pulmonary embolism treated with or without catheter-based therapy

Leiva O, Yang EH, Rosovsky RP, Alviar C, Bangalore S. In-hospital and readmission outcomes of patients with cancer admitted for pulmonary embolism treated with or[...]

FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis

Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta[...]